The use of Minimized Extracorporeal Circulation System has a Beneficial Effect on Hemostasis--A Randomized Clinical Study
Background. Conventional cardiopulmonary bypass (CPB) is associated with increased coagulation and fibrinolytic activity. A closed miniaturized bypass circuit (CorX) features a significantly reduced tubing set, an integrated pump, and an air removal system without a cardiotomy reservoir. In a prospective randomized trial, the effects on hemostasis were investigated while comparing CorX with conventional CPB in patients undergoing coronary artery bypass grafting.
Methods. Over a period of 1 year, 81 patients were randomly assigned either to the CorX system (n = 39, group A) or standard CPB system (n = 42, group B). Primary endpoints were platelet count, plasmin-antiplasmin complex (PAP), prothrombin fragments 1+2 (F1+F2), D-dimers, and fibrinogen. Secondary end-points were hematocrit, blood loss in the first 12 hours postoperatively, transfused packed red blood cells, and fresh frozen plasma in the first 24 hours postoperatively. In addition, we analyzed partial thromboplastin time, prothrombin time, and antithrombin III.
Results. After aortic declamping, PAP complex and prothrombin F1+F2 were significantly lower in group A than in group B. The difference in D-dimers between groups reached significance at 1 hour post-CPB. Hematocrit values at the end of CPB measured 26 ± 6% in group A versus 22 ± 4% in group B (P = .01). The rest of the observed parameters did not significantly differ between groups.
Conclusion. Postoperative blood loss was not reduced in the present study. However, the use of the CorX system leads to a significant suppression of activation of coagulation and fibrinolytic cascades compared to conventional CPB, suggesting that miniaturized extracorporeal circuits are a step forward toward reduced imbalance of hemostasis in cardiac surgery.
Abdel-Rahman U, Ozaslan F, Risteski PS, et al. 2005. Initial experience with a minimized extracorporeal bypass system: is there a clinical benefit? Ann Thorac Surg 80:238-43.nCenters for Disease Control and Prevention. 2003. Life expectancy at birth, at 65 years of age, and at 75 years of age, according to race and sex: United States, selected years 1900-2001. Table 27. (Accessed December 16, 2004, at http://www.cdc.gov/nchs/data/hus/tables/2003/03hus027.pdf).nDaniel S. 1996. Review on the multifactorial aspects of bioincompatibility in CPB. Perfusion 11:246-55.nEdmunds, LH. 2004. Cardiopulmonary bypass after 50 years. N Engl J Med 351;16:1603-6.nFolliguet TA, Villa E, Vandeneyden F, Laborde F. 2003. Coronary artery bypass graft with minimal extracorporeal circulation. Heart Surg Forum 6:297-301.nGibbon JH Jr. 1954. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 37:171-85.nChai PJ, Nassar R, Oakeley AE, et al. 2000. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 101:541-6.nFallen D, Komorowski B, Groh M. 2003. Perfusion-assisted beating heart CABG with a miniature bypass system is associated with improved outcomes compared to traditional CPB-supported CABG. Heart Surg Forum 6:207-8.nFromes Y, Gaillard D, Ponzio O, et al. 2002. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 22:527-33.nMueller XM, Jegger D, Augstburger M, Horisberger J, Godar G, von Segesser LK. 2002. A new concept of integrated cardiopulmonary bypass circuit. Eur J Cardiothorac Surg 21:840-6.nNaik SK, Knight A, Elliot M. 1991. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation 84(Suppl III):422-31.nNashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. 1999. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16:9-13.nZahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF. 1999. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass Cardiovasc Res 41:722-30.nWimmer-Greinecker G, Matheis G, Martens S, Oremek G, Abdel-Rahman U, Moritz A. 1999. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar results and minor bio chemical differences. Eur J Cardio-thorac Surg 16:211-17.nvon Segesser LK, Tozzi P, Mallbiabrrena I, Jegger D, Horisberger J, Corno A. 2003. Miniaturization in cardiopulmonary bypass. Perfusion 18:219-224.nWachtfogel YT, Kucich U, Hack CE, et al. 1993. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106:1-9.nWestaby S. Organ dysfunction after cardiopulmonary bypass. 1987. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 13:89-95.nKirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. 1983. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-57.nLuciani GB, Menon T, Vecchi B, et al. 2003. Modified ultrafiltration reduces morbidity after adult cardiac operations: a prospective, randomized clinical trial. Circulation 104(Suppl I):253-9.nMuehrcke DD, McCarthy PM, Kottke-Marchant K, et al. 1996. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized masked clinical trial. J Thorac Cardiovasc Surg 112:472-83.nGourlary T. 2001. Biomaterial developement for cardiopulmonary bypass. Perfusion 16:380-391.nGu Y, van Oeveren W, Akkerman C, Boonstra P, Huyzen R, Wildevuur C. 1993. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55:917-22.nHill GE, Alonso A, Thiele GM, Robbins RA. 1994. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 79:23.nHill GE, Alonso A, Spurzem JR, et al. 1995. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110:1658-62.nJansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. 1992. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744-8.nMatheis G. 2001. Leukocyte filtration in cardiac surgery: a review. Perfusion 16:361-70.nMou SS, Giroir BP, Molitor-Kirsch EA, et al. 2004. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med 351:1635-44.nMurase M, Usui A, Tomita Y, et al. 1993. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 88(Suppl II):432-6.nScholz M, Simon A, Matheis G, et al. 2002. Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery. Inflamm Res 51:363-8.nProndzinsky R, Knüpfer A, Lappnow H, et al. 2005. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 129:760-6.nRemadi JP, Marticho P, Butoi I, et al. 2004. Clinical experience with the mini-extracorporeal circulation system: an evolution or a revolution? Ann Thorac Surg 77:2172-6.nVaislic C, Bical O, Farge C, et al. 2003. Totally minimized extracorporeal circulation: an important benefit for coronary artery bypass grafting in Jehovah's witnesses. Heart Surg Forum 6:307-10.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).